Combined Index to USP 41 and NF 36, Volumes 1–5, Including Second Supplement
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
30 Day Change Notice Effective Date
30 Day Change Notice Effective Date: January 1st, 2021 NEW PREFERRED DRUGS THERAPEUTIC CLASS NO PA REQUIRED PREFERRED Central Nervous System (CNS) Agents: Anticonvulsants Clobazam (Generic of Onfi) Central Nervous System (CNS) Agents: Multiple Aubagio EndocrineSclerosis Agents: Osteoporosis-Bone Ossification Forteo Enhancers Gastrointestinal Agents: Anti-Emetics Bonjesta Genitourinary Agents: Benign Prostatic Hyperplasia Alfuzosin (Generic of Uroxatral) Dutasteride (Generic of Avodart) Genitourinary Agents: Electrolyte Depleter Agents Sevelamer (Generic of Renagel and Renvela) Infectious Disease Agents: Antibiotics-Macrolides Eryped Infectious Disease Agents: Antivirals-HIV Atazanavir Sulfate Oral Powder (Generic of Reyataz) Tivicay PD Infectious Disease Agents: Antibiotics-Tetracyclines Vibramycin Suspension (no PA Required for age 12 or under) Ophthalmic Agents: Antibiotics and Antibiotic -Steroid Neomycin/Polymyxin/Bacitracin/Hydrocortisone Ointment Combination Drops and Ointments Ophthalmic Agents: Glaucoma Agents Dorzolamide/Timolol (Generic of Cosopt PF) NEW CLINICAL PA REQUIRED “PREFERRED” DRUGS THERAPEUTIC CLASS CLINICAL PA REQUIRED PREFERRED Blood Formation, Coagulation, and Thrombosis Agents: Corifact Hemophilia Factors Immunomodulator Agents for Systemic Inflammatory Taltz Disease Immunomodulator Agents for Systemic Inflammatory Xeljanz 5mg Disease NEW STEP THERAPY REQUIRED “PREFERRED” THERAPEUTIC CLASS STEP THERAPY REQUIRED “PREFERRED” Central nervous System (CNS) Agents: Anti-Migraine, Aimovig Prophylaxis Treatment Ajovy -
Active Pharmaceutical Ingredients
Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes). -
INTEGRIS Formulary July 2017
INTEGRIS Formulary July 2017 Foreword FORMULARY EXCLUDED THERAPEUTIC DRUG This document represents the efforts of the MedImpact Healthcare Systems THERAPEUTIC DRUGS CLASS Pharmacy and Therapeutics (P & T) and Formulary Committees to provide ALTERNATIVES physicians and pharmacists with a method to evaluate the safety, efficacy and cost- clindamycin/tretinoin, ACNE AGENTS, effectiveness of commercially available drug products. A structured approach to the VELTIN drug selection process is essential in ensuring continuing patient access to rational ZIANA TOPICAL drug therapies. The ultimate goal of the MedPerform Formulary is to provide a morphine sulfate ER process and framework to support the dynamic evolution of this document to guide tablets, oxycodone ANALGESICS, KADIAN prescribing decisions that reflect the most current clinical consensus associated ER, NUCYNTA, NARCOTICS with drug therapy decisions. NUCYNTA ER ANALGESICS, This is accomplished through the auspices of the MedImpact P & T and Formulary BELBUCA BUTRANS PATCH Committees. These committees meet quarterly and more often as warranted to NARCOTICS ensure clinical relevancy of the Formulary. To accommodate changes to this ABSTRAL, document, updates are made accessible as necessary. FENTORA, fentanyl citrate ANALGESICS, LAZANDA, lozenge NARCOTICS As you use this Formulary, you are encouraged to review the information and ONSOLIS, provide your input and comments to the MedImpact P & T and Formulary SUBSYS Committees. immediate-release GRALISE ANTICONVULSANTS The MedImpact P & T -
Printed Formulary Catalog Basic
Scripps Health Formulary July 2016 Foreword Pharmacy and Therapeutics Committee. MedImpact approves such multi- This document represents the efforts of the MedImpact Healthcare Systems source drugs for addition to the MAC list based on the following criteria: Pharmacy and Therapeutics (P & T) and Formulary Committees to provide physicians A multi-source drug product manufactured by at least one (1) nationally and pharmacists with a method to evaluate the safety, efficacy and cost-effectiveness marketed company. of commercially available drug products. A structured approach to the drug selection At least one (1) of the generic manufacturer’s products must have an “A” process is essential in ensuring continuing patient access to rational drug therapies. rating or the generic product has been determined to be unassociated with The ultimate goal of the Portfolio Formulary is to provide a process and framework to efficacy, safety or bioequivalency concerns by the MedImpact P & T support the dynamic evolution of this document to guide prescribing decisions that Committee. reflect the most current clinical consensus associated with drug therapy decisions. Drug product will be approved for generic substitution by the MedImpact P & T Committee. This is accomplished through the auspices of the MedImpact P & T and Formulary Committees. These committees meet quarterly and more often as warranted to ensure This list is reviewed and updated periodically based on the clinical literature and clinical relevancy of the Formulary. To accommodate changes to this document, pharmacokinetic characteristics of currently available versions of these drug updates are made accessible as necessary. products. As you use this Formulary, you are encouraged to review the information and provide If a member or physician requests a brand name product in lieu of an approved your input and comments to the MedImpact P & T and Formulary Committees. -
Malta Medicines List April 08
Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal -
Index B Alphabetical List of Pharmaceutical Product Names
INDEX B ALPHABETICAL LIST OF PHARMACEUTICAL PRODUCT NAMES PRODUCT NAME Page PRODUCT NAME Page 292 97 ACYCLOVIR 17 3TC (EDS) 14 ACYCLOVIR 17 5-AMINOSALICYLIC ACID (MESALAMINE) 170 " 18 ABACAVIR SO4 13 ADALAT XL 57 ABACAVIR SO4/LAMIVUDINE 13 ADALIMUMAB 220 ABACAVIR SO4/LAMIVUDINE/ZIDOVUDINE 13 ADAPALENE 206 ABATACEPT 220 ADCIRCA (EDS) 89 ABILIFY (EDS) 123 ADEFOVIR DIPIVOXIL 18 ACARBOSE 187 ADHESIVE WIPES (EDS) 239 ACCEL PIOGLITAZONE (EDS) 190 ADVAGRAF (EDS) 231 ACCEL TOPIRAMATE 112 ADVAIR (EDS) 33 ACCEL-CITALOPRAM 114 ADVAIR DISKUS (EDS) 33 ACCOLATE (EDS) 232 AGGRENOX (EDS) 87 ACCU-CHEK 1 MINI (EDS) 238 AGRYLIN 221 ACCU-CHEK 2 MINI (EDS) 238 AIROMIR 32 ACCU-CHEK ADVANTAGE 142 ALCOHOL PREP 234 ACCU-CHEK AVIVA 142 ALCOHOL SWAB 234 ACCU-CHEK COMPACT 142 ALDACTAZIDE-25 82 ACCU-CHEK FASTCLIX MOBILE 234 ALDACTAZIDE-50 82 ACCU-CHEK LINKASSIST (EDS) 239 ALDACTONE 148 ACCU-CHEK MOBILE 142 ALDARA (EDS) 209 ACCU-CHEK MULTICLIX 234 ALENDRONATE (EDS) 220 ACCU-CHEK RAPID D (EDS) 236 ALENDRONATE SODIUM 220 " 237 ALENDRONATE SODIUM (EDS) 220 " 238 ALENDRONATE SODIUM/VITAMIN D3 ACCU-CHEK SPIRIT (EDS) 236 (CHOLECALCIFEROL) 220 ACCU-CHEK TENDER 1 (EDS) 238 ALERTEC (EDS) 133 " 239 ALESSE 181 ACCU-CHEK TENDER 2 (EDS) 238 ALFACALCIDOL 217 " 239 ALFUZOSIN 220 ACCU-CHEK ULTRAFLEX 1 (EDS) 237 ALGLUCOSIDASE ALFA 221 " 238 ALLOPURINOL 221 ACCU-CHEK ULTRAFLEX 2 (EDS) 237 ALMOTRIPTAN MALATE 33 " 238 ALOMIDE 158 ACCUPRIL 79 ALPHAGAN 157 ACCURETIC 80 ALPHAGAN P 157 ACCUTANE 209 ALPRAZOLAM 134 ACCUTREND 142 ALPRAZOLAM 134 ACEBUTOLOL 48 ALTACE 80 ACEBUTOLOL HCL 48 " 81 -
Metal Complexes of Quinolone Antibiotics and Their Applications: an Update
Molecules 2013, 18, 11153-11197; doi:10.3390/molecules180911153 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Metal Complexes of Quinolone Antibiotics and Their Applications: An Update Valentina Uivarosi Department of General and Inorganic Chemistry, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 6 Traian Vuia St, Bucharest 020956, Romania; E-Mail: [email protected]; Tel.: +4-021-318-0742; Fax: +4-021-318-0750 Received: 8 August 2013; in revised form: 2 September 2013 / Accepted: 2 September 2013 / Published: 11 September 2013 Abstract: Quinolones are synthetic broad-spectrum antibiotics with good oral absorption and excellent bioavailability. Due to the chemical functions found on their nucleus (a carboxylic acid function at the 3-position, and in most cases a basic piperazinyl ring (or another N-heterocycle) at the 7-position, and a carbonyl oxygen atom at the 4-position) quinolones bind metal ions forming complexes in which they can act as bidentate, as unidentate and as bridging ligand, respectively. In the polymeric complexes in solid state, multiple modes of coordination are simultaneously possible. In strongly acidic conditions, quinolone molecules possessing a basic side nucleus are protonated and appear as cations in the ionic complexes. Interaction with metal ions has some important consequences for the solubility, pharmacokinetics and bioavailability of quinolones, and is also involved in the mechanism of action of these bactericidal agents. Many metal complexes with equal or enhanced antimicrobial activity compared to the parent quinolones were obtained. New strategies in the design of metal complexes of quinolones have led to compounds with anticancer activity. -
The Organic Chemistry of Drug Synthesis
The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date. -
| Secretion !------Cortisol Cortisol US 7,053,228 B2 Page 2
US007053228B2 (12) United States Patent (10) Patent No.: US 7,053,228 B2 Burton et al. (45) Date of Patent: May 30, 2006 (54) SULFUR ANALOGUES OF (52) U.S. Cl. ...................... 552/512; 514/179; 514/180; 21-HYDROXY-6,19-OXIDOPROGESTERONE 552/510; 549/29: 549/41 (21OH-60P). FOR TREATING EXCESS OF (58) Field of Classification Search ................ 514/179, GLUCOCORTICODS 514/180, 181: 552/653,510,512; 549/41 (75) Inventors: Gerardo Burton, Prov. de Buenos See application file for complete search history. Aires (AR); Carlos P. Lantos, Buenos Aires (AR); Adriana Silvia Veleiro, (56) References Cited Martinez (AR) U.S. PATENT DOCUMENTS (73) Assignee: Applied Research Systems ARS Holding N.V., Curacao (NL) 6,303,591 B1 * 10/2001 Burton et al. ............... 514f179 FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 EP O 348 910 1, 1990 U.S.C. 154(b) by 148 days. EP O 903 146 3, 1999 OTHER PUBLICATIONS (21) Appl. No.: 10/363,860 “Synthesis of 21-hydroxy-11, 19-oxidopregn-4-ene-320 (22) PCT Filed: Sep. 17, 2001 dione and 21-hydroxy-6, 19-oxidopregn-4-ene-320-dione': Steroids vol. 60, No. 3, pp. 268-271, 1995.* (86). PCT No.: PCT/EPO1/10750 (Continued) S 371 (c)(1), (2), (4) Date: Aug. 20, 2003 Primary Examiner Sabiha Qazi (74) Attorney, Agent, or Firm Oblon, Spivak, McClelland, (87) PCT Pub. No.: WO02/22647 Maier & Neustadt, P.C. PCT Pub. Date: Mar. 21, 2002 (57) ABSTRACT (65) Prior Publication Data The present invention is related to novel 21-hydroxy-6.19 US 2004/002984.6 A1 Feb. -
Bacitracin B:0050 Medical Surveillance: Evaluation by a Qualified Allergist
B Bacitracin B:0050 Medical Surveillance: Evaluation by a qualified allergist. Kidney function tests. First Aid: In case of large-scale exposure, the directions for Molecular Formula: C H N O S 66 103 17 16 medicines (nonspecific, n.o.s.) would be applied as follows: Synonyms: Ayfivin; Baciguent; Baci-Jel; Baciliquin; Move victim to fresh air; call emergency medical care. If Bacitek ointment; Fortracin; Parentracin; Penitracin; not breathing, give artificial respiration. If breathing is diffi- Topitracin; Zutracin cult, give oxygen. In case of contact with material, immedi- CAS Registry Number: 1405-87-4 ® ately flush skin or eyes with running water for at least RTECS Number: CP0175000 15 min. Speed in removing material from skin is of extreme UN/NA & ERG Number: UN3249 (medicine, solid, toxic, importance. Remove and isolate contaminated clothing and n.o.s.)/151 shoes at the site. Keep victim quiet and maintain normal EC Number: 215-786-2 body temperature. Effects may be delayed; keep victim Regulatory Authority and Advisory Bodies under observation. Listed on the TSCA inventory. Storage: Color Code—Green: General storage may be used. List of Acutely Toxic Chemicals, Chemical Emergency Shipping: The DOT category of medicine, solid, toxic, n.o.s. Preparedness Program (EPA) and formerly on CERCLA/ calls for the label of “POISONOUS/TOXIC MATERIALS.” SARA 40CFR302, Table 302.4 Extremely Hazardous Bacitracin would fall in Hazard Class 6.1 and in Packing Substances List. Dropped from listing in 1988. Group III. Listed on Canada’s DSL List. Spill Handling: Evacuate and restrict persons not wearing WGK (German Aquatic Hazard Class): No value assigned. -
The Σ1 Receptor Engages the Redox-Regulated HINT1 Protein to Bring Opioid
Page 1 of 110 Original Research Communication The σ1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control María Rodríguez-Muñoz1, Pilar Sánchez-Blázquez1, Raquel Herrero-Labrador1, Ricardo Martínez-Murillo1, Manuel Merlos2, José Miguel Vela2, Javier Garzón1 1Cajal Institute, Consejo Superior de Investigaciones Científicas (CSIC), Avenida Doctor Arce, 37. 28002 Madrid, Spain. 2Drug Discovery & Preclinical Development, Esteve. Scientific Park of Barcelona, Bardiri y Reixac 4-8, 08028, Barcelona, Spain. Running head: σ1R engages NMDAR control on MOR Correspondence to: Javier Garzón. Neurofarmacología, Instituto Cajal, Avenida Doctor Arce 37, 28002 Madrid, Spain. Tel: 34 91 5854733, Fax: 34 91 5854754. E- mail: [email protected] Antioxidants & Redox Signaling Word count: 6950 Reference number: 70 Grayscale Illustrations: Figures 5, 6, 8 and 9 Color Illustrations: Figures 3 and 4 Color online, B&W print: Figures 1, 2, 7, and 10 The 1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA negative control (doi: 10.1089/ars.2014.5993) This article has been peer-reviewed and accepted for publication, but yet to undergo copyediting proof correction. The final published version may differ from this proof. 1 Page 2 of 110 2 Abstract Aims: The in vivo pharmacology of the sigma 1 receptor (σ1R) is certainly complex; however, σ1R antagonists are of therapeutic interest because they enhance mu-opioid receptor (MOR)-mediated antinociception and reduce neuropathic pain. Thus, we investigated whether the σ1R is involved in the negative control that glutamate N- methyl-D-aspartate receptors (NMDARs) exert on opioid antinociception. -
Pregn-5-Ene-3,20-Dione, Pregnenolone and Related Progestins on Ovulation in Pmsg-Treated Immature Rats
EFFECT OF 5\m=infty\-DIHYDROPROGESTERONE, PREGN-5-ENE-3,20-DIONE, PREGNENOLONE AND RELATED PROGESTINS ON OVULATION IN PMSG-TREATED IMMATURE RATS B. N. SRIDHARAN, R. K. MEYER and H. J. KARAVOLAS Departments of Zoolog? and Physiological Chemistry, The Endocrinology-Reproductive Physiology Program, University of Wisconsin, Madison, Wisconsin 53706, U.S.A. (Received 9th January 1973) Summary. The facilitative effects of certain progestational steroids on ovulation were investigated by using 25-day-old female rats which had been treated on Day 22 with a non-ovulatory dose of PMSG (12 i.u.). Ovulation was caused by treatment with pregnenolone or progesterone on the morning of Day 24. The dose of pregnenolone required was higher than that ofprogesterone. Progesterone had this effect throughout the morning of Day 24, while prenenolone was only effective between 07.00 and 10.00 hours on Day 24. The two metabolites of progesterone in the hypothalamus and uterus, 5\g=a\-dihydroprogesteroneand 3\g=a\\x=req-\ hydroxy-5\m=infty\-pregnan-20-one,were also tested for their ability to cause ovulation. Although 5\g=a\-dihydroprogesteronepossessed this ability, a dose three to four times that of progesterone was required to produce a comparable effect. Doses of up to 1 \m=.\5mg 3\g=a\-hydroxy-5\g=a\-pregnan-20-one were without effect. Neither 17\g=a\-hydroxypregnenolonenor 17\g=a\-hydroxy- progesterone had any effect in influencing ovulation. Pregn-5-ene-3,20-dione had a facilitative ability comparable to that of progesterone in doses of 0\m=.\25mg or higher.